2020
Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease
Collins D, Sundar R, Constantinidou A, Dolling D, Yap T, Popat S, O’Brien M, Banerji U, de Bono J, Lopez J, Tunariu N, Minchom A. Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. BMC Cancer 2020, 20: 1210. PMID: 33298007, PMCID: PMC7724793, DOI: 10.1186/s12885-020-07662-y.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsBrain NeoplasmsClinical Trials, Phase I as TopicCombined Modality TherapyDiagnostic ImagingFemaleHumansKaplan-Meier EstimateLiver NeoplasmsLung NeoplasmsMaleMesothelioma, MalignantMiddle AgedPeritoneal NeoplasmsPleural NeoplasmsProportional Hazards ModelsRetrospective StudiesConceptsDistant metastasisPeritoneal metastasisMPM patientsTreatment paradigmCohort of MPM patientsFrequency of distant metastasesIncidence of bone metastasesPresence of distant metastasesPattern of metastatic spreadDistant metastatic diseaseDistant metastatic disseminationBackgroundMalignant pleural mesotheliomaPresence of symptomsIncidence of boneMetastatic diseaseMetastatic sitesBone metastasesOverall survivalMetastatic spreadContralateral lungPrognostic implicationsMetastatic disseminationRadiological investigationsRetrospective studyPleural mesotheliomaPonatinib is a potential therapeutic approach for malignant pleural mesothelioma
Yang YW, Marrufo A, Chase J, Woodard GA, Jablons DM, Lemjabbar-Alaoui H. Ponatinib is a potential therapeutic approach for malignant pleural mesothelioma. Experimental Lung Research 2020, 47: 9-25. PMID: 33107354, DOI: 10.1080/01902148.2020.1836691.Peer-Reviewed Original ResearchConceptsMalignant pleural mesotheliomaPonatinib treatmentPleural mesotheliomaMPM linesTherapeutic approachesPotential therapeutic approachExpression levelsNew therapeutic strategiesHuman MPM cellsMPM therapyPSTAT5 levelsWestern blot analysisMPM patientsMPM treatmentDeadly malignancyLevels of γH2AXPotential utilityTherapeutic strategiesTumor growthMPM cellsPathway inhibitionTumor modelPonatinibActivation of AblTumor samplesSurgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma
Woodard GA, Jablons DM. Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma. Translational Lung Cancer Research 2020, 9: s86-s91. PMID: 32206574, PMCID: PMC7082252, DOI: 10.21037/tlcr.2020.01.08.Peer-Reviewed Original ResearchMalignant pleural mesotheliomaExtrapleural pneumonectomyPleural mesotheliomaSurvival timePleurectomy decorticationSurgical resectionPatient selectionRetrospective single-institution reviewHigh perioperative mortality rateLonger overall survival timeLimited disease burdenMajor surgical resectionRadiation therapy trialsRadical Surgery trialPerioperative mortality rateSingle-institution reviewOverall survival timeShorter survival timeBiased patient selectionLonger survival timeElevated CRPAdvanced diseaseElevated plateletNodal diseaseMPM patients
2019
Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma
Stockhammer P, Ploenes T, Theegarten D, Schuler M, Maier S, Aigner C, Hegedus B. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma. Lung Cancer 2019, 139: 124-132. PMID: 31778960, DOI: 10.1016/j.lungcan.2019.11.013.Peer-Reviewed Original ResearchConceptsMalignant pleural mesotheliomaNon-malignant pleural diseasePleural effusionMPM patientsPleural mesotheliomaPrognostic stratificationNon-epithelioid malignant pleural mesotheliomaStage IV lung cancerEpithelioid malignant pleural mesotheliomaInferior overall survivalTGF-β levelsLevels of TGFLung cancer patientsChest CT scanOverall survivalSMRP levelsClinicopathological characteristicsDismal prognosisPleural diseaseTumor loadAggressive malignancyDisease stageCancer patientsLung cancerPrimary diagnosis1849P Pleural effusion TGF-beta is highly diagnostic and prognostic in malignant pleural mesothelioma
Stockhammer P, Ploenes T, Schuler M, Langer S, Aigner C, Hegedus B. 1849P Pleural effusion TGF-beta is highly diagnostic and prognostic in malignant pleural mesothelioma. Annals Of Oncology 2019, 30: v750-v751. DOI: 10.1093/annonc/mdz266.008.Peer-Reviewed Original ResearchMalignant pleural mesotheliomaNon-malignant pleural diseaseTGF-β levelsMPM patientsPleural mesotheliomaNon-epithelioid malignant pleural mesotheliomaMultivariate Cox regression modelWorse overall survivalCox regression modelFuture clinical trialsPleural effusion samplesAdvanced diseaseMultimodality treatmentOverall survivalDismal prognosisEpithelioid tumorsPleural effusionPleural diseaseAggressive malignancyClinical trialsPrognostic biomarkerPatientsReliable biomarkersEffusion samplesSignificant negative correlation
2017
Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma
Klikovits T, Stockhammer P, Laszlo V, Dong Y, Hoda MA, Ghanim B, Opitz I, Frauenfelder T, Nguyen-Kim TDL, Weder W, Berger W, Grusch M, Aigner C, Klepetko W, Dome B, Renyi-Vamos F, Oehler R, Hegedus B. Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma. Scientific Reports 2017, 7: 16456. PMID: 29184132, PMCID: PMC5705645, DOI: 10.1038/s41598-017-16551-7.Peer-Reviewed Original ResearchConceptsMalignant pleural mesotheliomaNon-malignant pleural diseasePlasma C4d levelsC4d levelsHealthy volunteersInduction chemotherapyMPM patientsPleural mesotheliomaTumor volumeMultivariate Cox regression modelEctopic lymphoid structuresBetter overall survivalCox regression modelHigher tumor volumeNew prognostic biomarkerPlasma C4dOverall survivalProgressive diseaseLymphoid structuresPleural diseaseC4d immunohistochemistryPrognostic biomarkerTumor stromaPatientsChemotherapeutic responsePatterns of metastases in malignant pleural mesothelioma in the modern era: Redefining the spread of an old disease.
Collins D, Constantinidou A, Sundar R, Chenard-Poirier M, Yap T, Banerji U, De Bono J, Lopez J, Tunariu N. Patterns of metastases in malignant pleural mesothelioma in the modern era: Redefining the spread of an old disease. Journal Of Clinical Oncology 2017, 35: 8556-8556. DOI: 10.1200/jco.2017.35.15_suppl.8556.Peer-Reviewed Original ResearchMalignant pleural mesotheliomaDrug Development UnitMetastatic patternBone metastasesPleural mesotheliomaCohort of MPM patientsAdvanced malignant pleural mesotheliomaMalignant pleural mesothelioma patientsEpithelioid malignant pleural mesotheliomaSymptomatic brain metastasesMedian overall survivalSecond-line therapySite of metastasisPattern of metastasisLytic bone metastasesFDG-PET imagingUnusual metastasesVisceral metastasesBrain metastasesMPM patientsOverall survivalLung metastasesMedian ageBone scanOmental disease
2016
Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma – A multi-institutional study
Hoda MA, Dong Y, Rozsas A, Klikovits T, Laszlo V, Ghanim B, Stockhammer P, Ozsvar J, Jakopovic M, Samarzija M, Brcic L, Bendek M, Szirtes I, Reid G, Kirschner MB, Kao SC, Opitz I, Weder W, Frauenfelder T, Nguyen-Kim TD, Aigner C, Klepetko W, van Zandwijk N, Berger W, Dome B, Grusch M, Hegedus B. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma – A multi-institutional study. European Journal Of Cancer 2016, 63: 64-73. PMID: 27288871, DOI: 10.1016/j.ejca.2016.04.018.Peer-Reviewed Original ResearchConceptsMalignant pleural mesotheliomaActivin A levelsMPM patientsActivin APleural mesotheliomaHigh activin A levelsNon-malignant pleural diseaseEpithelioid malignant pleural mesotheliomaEpithelioid MPM patientsTime of diagnosisLonger overall survivalNovel prognostic biomarkerMulti-institutional studyEnzyme-linked immunosorbent assayA levelsPlasma activinOverall survivalSurgical resectionActivin expressionHigh activinPleural diseasePoor prognosisClinicopathological variablesEpithelioid histologyHealthy controlsWhole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas
Kang HC, Kim HK, Lee S, Mendez P, Kim JW, Woodard G, Yoon JH, Jen KY, Fang LT, Jones K, Jablons DM, Kim IJ. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. Oncotarget 2016, 7: 8321-8331. PMID: 26824986, PMCID: PMC4884995, DOI: 10.18632/oncotarget.7032.Peer-Reviewed Original ResearchMeSH KeywordsBlotting, WesternExomeFemaleGenome, HumanHigh-Throughput Nucleotide SequencingHistone-Lysine N-MethyltransferaseHumansImmunoenzyme TechniquesLoss of HeterozygosityLung NeoplasmsMesotheliomaMesothelioma, MalignantMiddle AgedMutationPleural NeoplasmsPrognosisProtein MethyltransferasesReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSurvival RateConceptsMalignant pleural mesotheliomaPrimary cancerPleural mesotheliomaGenetic mechanismsDeep sequencingAdditional primary cancersMultiple primary cancersPrimary lung cancerPrimary cancer developmentAllelic lossNew genetic mechanismWhole-exome sequencingDistinct genomic alterationsMPM patientsRare malignancyPerineural invasionPoor prognosisTherapeutic optionsLung cancerLoss of heterozygosityTP53 mutationsCancer developmentPatientsExome sequencingCancer
2010
Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma
Du KL, Both S, Friedberg JS, Rengan R, Hahn SM, Cengel KA. Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma. Cancer Biology & Therapy 2010, 10: 425-429. PMID: 20699634, DOI: 10.4161/cbt.10.5.12616.Peer-Reviewed Original ResearchConceptsMalignant pleural mesotheliomaPlanning treatment volumeExtrapleural pneumonectomyPleural mesotheliomaRadiation therapyImproved local controlMedian radiation doseFuture prospective analysesTreatment of mesotheliomaNew treatment modalitiesIntraoperative photodynamic therapyQuality of lifePhotodynamic therapyIntraoperative adjuvantMultimodality therapyRadiation pneumonitisRespiratory failureSurgical debulkingContralateral lungMPM patientsDoses of radiationMechanical ventilationMultimodality approachLung toxicityTreatment modalities
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply